Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 119 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipoprotein(a) Clear all
Completed Phase 2 Interventional Results available

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

NCT05565742
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
LY3819469, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Mesa, Arizona • Pasadena, California • Santa Clarita, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

NCT01323153
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
dalcetrapib, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Pensacola, Florida • Saginaw, Michigan • Saint Cloud, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Production of Lipoproteins and Acetyl-CoA During a Ketogenic Diet

NCT03901014
View directory record Official record
Conditions
Cholesterol Metabolism, Ketone Metabolism
Interventions
Standard American diet, Very low carbohydrate diet
Other
Lead sponsor
Touro University, California
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 8:15 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

NCT05972278
View directory record Official record
Conditions
Lipid Metabolism
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

NCT05787002
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Not applicable Interventional

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

NCT05378529
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Lp(a) Screening
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
39,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

NCT01133366
View directory record Official record
Conditions
Healthy
Interventions
warfarin sodium, mipomersen sodium; warfarin sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jul 22, 2026, 8:15 AM EDT
Recruiting Phase 3 Interventional

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

NCT07293260
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
35 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Bridgeport, Connecticut • Jacksonville, Florida • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

NCT00746811
View directory record Official record
Conditions
Primary Hypercholesterolemia
Interventions
P-OM3, Placebo
Drug
Lead sponsor
Provident Clinical Research
Other
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Jul 22, 2026, 8:15 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 22, 2026, 8:15 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes

NCT01098994
View directory record Official record
Conditions
Type 1 Diabetes, Heart Disease
Interventions
Vitamin E, Dummy pills
Dietary Supplement · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Jul 22, 2026, 8:15 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 8:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cardioprotective Effects of Freeze Dried Grape Powder on Blood Pressure and Plasma Lipids/Lipoproteins

NCT03659695
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 22, 2026, 8:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

NCT02651675
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Jul 22, 2026, 8:15 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

NCT00327002
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
LY518674
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

NCT01375777
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals

NCT01404897
View directory record Official record
Conditions
Cardiovascular Disease, Dyslipidemia, Blood Pressure
Interventions
Dietary Intervention
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Jul 22, 2026, 8:15 AM EDT
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Jul 22, 2026, 8:15 AM EDT